Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) have earned an average rating of “Hold” from the thirteen ratings firms that are presently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell rating and nine have issued a hold rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $14.44.

A number of equities research analysts recently issued reports on the stock. Goldman Sachs Group, Inc. (The) assumed coverage on shares of Momenta Pharmaceuticals in a research note on Thursday, September 28th. They set a “neutral” rating and a $18.00 price target on the stock. Barclays PLC reissued an “equal weight” rating and issued a $16.00 target price (down previously from $17.00) on shares of Momenta Pharmaceuticals in a research note on Wednesday, October 4th. Zacks Investment Research raised shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research note on Wednesday, October 4th. Stifel Nicolaus reissued a “hold” rating and issued a $15.00 target price (down previously from $22.00) on shares of Momenta Pharmaceuticals in a research note on Wednesday, October 4th. Finally, Maxim Group set a $6.00 target price on shares of Momenta Pharmaceuticals and gave the company a “sell” rating in a research note on Thursday, August 3rd.

In other news, President Craig A. Wheeler sold 35,667 shares of the company’s stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $19.03, for a total value of $678,743.01. Following the transaction, the president now directly owns 286,121 shares in the company, valued at $5,444,882.63. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, President Craig A. Wheeler sold 4,116 shares of the company’s stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $15.07, for a total transaction of $62,028.12. Following the completion of the transaction, the president now owns 269,231 shares in the company, valued at $4,057,311.17. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 64,372 shares of company stock worth $1,146,002. Company insiders own 4.40% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC grew its holdings in shares of Momenta Pharmaceuticals by 3.3% in the second quarter. FMR LLC now owns 11,125,193 shares of the biotechnology company’s stock worth $188,015,000 after purchasing an additional 351,743 shares during the last quarter. BlackRock Inc. grew its holdings in Momenta Pharmaceuticals by 7.1% during the 2nd quarter. BlackRock Inc. now owns 9,400,485 shares of the biotechnology company’s stock worth $158,868,000 after acquiring an additional 626,415 shares in the last quarter. Vanguard Group Inc. grew its holdings in Momenta Pharmaceuticals by 4.9% during the 2nd quarter. Vanguard Group Inc. now owns 6,243,767 shares of the biotechnology company’s stock worth $105,519,000 after acquiring an additional 290,090 shares in the last quarter. State Street Corp grew its holdings in Momenta Pharmaceuticals by 8.1% during the 2nd quarter. State Street Corp now owns 2,653,427 shares of the biotechnology company’s stock worth $44,842,000 after acquiring an additional 197,978 shares in the last quarter. Finally, Palo Alto Investors LLC grew its holdings in Momenta Pharmaceuticals by 1.6% during the 2nd quarter. Palo Alto Investors LLC now owns 1,787,576 shares of the biotechnology company’s stock worth $30,210,000 after acquiring an additional 28,200 shares in the last quarter. Hedge funds and other institutional investors own 91.19% of the company’s stock.

Shares of Momenta Pharmaceuticals (MNTA) opened at $13.70 on Friday. Momenta Pharmaceuticals has a 12 month low of $11.85 and a 12 month high of $19.90.

Momenta Pharmaceuticals (NASDAQ:MNTA) last released its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.47) by $0.03. The company had revenue of $24.09 million for the quarter, compared to the consensus estimate of $29.58 million. Momenta Pharmaceuticals had a negative net margin of 55.61% and a negative return on equity of 16.20%. Momenta Pharmaceuticals’s revenue was down 17.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.26) earnings per share. equities research analysts expect that Momenta Pharmaceuticals will post -1.16 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/11/19/momenta-pharmaceuticals-inc-mnta-given-consensus-rating-of-hold-by-brokerages.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Analyst Recommendations for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.